loader
Please Wait
Applying Filters...

Seqens Seqens

X

List of All Manufacturers & Suppliers for 213491 Licensing, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations listed on PharmaCompass.com

Client Virtual Booth
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 CYSTEAMINE BITARTRATE (2)

filter

01 HORIZON (2)

filter

01 GRANULE, DELAYED RELEASE;ORAL (2)

filter

01 EQ 300MG BASE/PACKET (1)

02 EQ 75MG BASE/PACKET (1)

filter

01 USA (2)

URL Supplier Web Content
GRANULE, DELAYED RELEA...
EQ 75MG BASE/PACKET
PROCYSBI
USA
213491
2020-02-14
RX
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
GRANULE, DELAYED RELEA...
EQ 300MG BASE/PACKET
PROCYSBI
USA
213491
2020-02-14
RX
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for CTD TGA MCC DOSSIER APPLICATION 213491

Looking for CTD TGA MCC DOSSIER APPLICATION 213491 2

19

Horizon Therapeutics, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is CYSTEAMINE BITARTRATE, with a corresponding application number 213491 and regulatory information .

proudly manufactured in the

approval since 2020-02-14

Horizon Therapeutics's PROCYSBI GRANULE, DELAYED RELEASE;ORAL, medication with EQ 75MG BASE/PACKET of CYSTEAMINE BITARTRATE.

18

Horizon Therapeutics, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is CYSTEAMINE BITARTRATE, with a corresponding application number 213491 and regulatory information .

proudly manufactured in the

approval since 2020-02-14

Horizon Therapeutics's PROCYSBI GRANULE, DELAYED RELEASE;ORAL, medication with EQ 300MG BASE/PACKET of CYSTEAMINE BITARTRATE.

Post Enquiry
POST ENQUIRY